Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Splanchnic blood flow regulation pathway
- Molecular classification
- Other (Regulatory pathway, not a molecule)
01
Overview
The splanchnic blood flow regulation pathway encompasses the network of physiological and molecular mechanisms governing the distribution and quantity of blood delivered to the splanchnic organs, including the gastrointestinal tract, pancreas, spleen, and liver. Regulation occurs through intrinsic (myogenic and metabolic autoregulation), neural (sympathetic vasoconstriction, parasympathetic vasodilation), hormonal (vasopressin, angiotensin II, adrenalin, incretins), and humoral (local metabolites such as adenosine, nitric oxide) means. This pathway is crucial for digestion, nutrient absorption, and maintaining systemic hemodynamic stability; dysregulation underlies several pathologies including shock, liver cirrhosis with portal hypertension, gut ischemia, and various postoperative complications.
- Other names
- Splanchnic circulation regulationRegulation of splanchnic blood flow
02
Mechanism of action
Vasoconstriction via adrenergic (sympathetic, α1) and vasopressinergic (V1) receptors Vasodilation via parasympathetic (acetylcholine-mediated nitric oxide release) and by vasodilatory mediators (adenosine, kinins, local metabolites, incretins)
03
Biological functions
Regulation of vascular toneDistribution of cardiac outputNutrient absorptionMetabolic homeostasisBlood volume reservoirAutoregulation of gastrointestinal perfusion
04
Disease associations
Cardiovascular diseasePortal hypertensionIschemic bowel diseaseHepatic failureSepsisPost-surgical complications (e.g., postcoarctectomy syndrome)
05
Safety considerations
Hypoperfusion leading to intestinal ischemia if pathologically reducedExcess vasoconstriction (from drugs like vasopressin) may cause gut ischemiaVasodilation in portal hypertension aggravates disease and contributes to complications like variceal bleeding, ascites, hepatorenal syndrome
06
Interacting drugs
Vasopressin and analogues (V1 receptor agonists used for splanchnic vasoconstriction)
4 more in the full profile.
Beyond the preview
Go deeper on Splanchnic blood flow regulation pathway.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Splanchnic blood flow regulation pathway.